Despite the urgent need for novel treatments, drug development for cognitive impairment associated with schizophrenia has been challenging, due to limited understanding, high trial failures, and few potential targets in the treatment regime.
Iclepertin (BI 425809), an investigational asset, is a GlyT1 inhibitor being developed by Boehringer Ingelheim that modulates the NMDA receptor function, a key aspect of CIAS, addressing the cognitive symptoms that are a significant burden for individuals with schizophrenia.
A US FDA-designated drug, Iclepertin, has the potential to fill the gap, and positive outcomes from Phase I and II trials that show iclepertin’s safety...
